Vistagen's Nasal Spray Shows Efficacy In Menopausal Hot Flashes
Portfolio Pulse from Vandana Singh
Vistagen Therapeutics announced that its investigational neuroactive nasal spray, PH80, demonstrated statistically significant efficacy in treating menopausal hot flashes in a Phase 2A study. PH80 was well-tolerated with no serious adverse events, and showed a significant reduction in the daily number of hot flashes compared to the placebo.
June 07, 2023 | 5:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vistagen's PH80 nasal spray demonstrated significant efficacy in treating menopausal hot flashes in a Phase 2A study, potentially expanding the company's product offerings.
The positive results from the Phase 2A study indicate that Vistagen's PH80 nasal spray could become a successful treatment for menopausal hot flashes. This could potentially expand the company's product offerings and increase its market share in the healthcare sector. However, the stock price is down 9.91% at $2.69, which could be due to other factors or market conditions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100